secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090878
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing
---------------------------------------------------------------------

- Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.
- Cash unchanged at $9.1M as of June 30, 2023; no revenue reported.
- Phase 2b trial for ibezapolstat in C. difficile: 28 sites enrolling; 5 patients needed for interim IDMC review.
- R&D expenses rose to $1.7M (Q2 2023) from $0.9M (Q2 2022) driven by Phase 2b costs.
- CARB-X declined grant for ACX375C pre-clinical candidate; encouraged re-application.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/0001104659-23-090878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/tm2323535d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer